ClinicalTrials.gg
CompletedNCT03978520SLEekUpdated Jul 21, 2023Results posted

A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

A Phase 2 interventional study of Elsubrutinib and Placebo for elsubrutinib in Systemic Lupus Erythematosus (SLE), sponsored by AbbVie. Completed at 160 sites in 21 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-21.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
341
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.

Enrollment
63rd of 407
341 · median 70
Started
2019
with 18 others
Phase 2
120 of 477
10 open now
Registered
293rd of 477
by date

Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 63rd largest by enrollment of the 407 interventional ones that give a count, is one of 19 that started in 2019, is one of 120 in phase 2, and was the 293rd registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 477 studies in Lupus Erythematosus, Systemic with a site in United States, or all of them as a file.
02

Study summary

The main objective of this study was to evaluate the safety and efficacy of elsubrutinib, upadacitinib (UPA), and ABBV-599 (elsubrutinib/upadacitinib) High Dose and Low Dose combinations vs placebo for the treatment of signs and symptoms of Systemic Lupus Erythematosus (SLE) in participants with moderately to severely active SLE and to define doses for further development.

03

Conditions studied

  • Systemic Lupus Erythematosus (SLE)

Keywords

  • Systemic Lupus Erythematosus (SLE)
  • ABBV-105
  • Upadacitinib
  • ABBV-599
  • Elsubrutinib
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has clinical diagnosis of Systemic Lupus Erythematosus (SLE) at least 24 weeks prior to Screening, meeting at least 4 of the 11 revised Criteria for Classification of SLE according to the 1997 Update of the 1982 American College of Rheumatology (ACR) OR meeting at least 4 of the 2012 SLICC classification criteria, including at least 1 clinical criterion and 1 immunologic criterion.
  • At Screening, must have at least one of the following:

    • antinuclear antibody (ANA)+ (titer ≥ 1:80)
    • anti-dsDNA+
    • anti-Smith+
  • SLEDAI-2K (SLE Disease Activity Index) ≥ 6 despite background therapy as reported and independently adjudicated (clinical score ≥ 4, excluding lupus headache and/or organic brain syndrome) at Screening:

    • If 4 points of the required entry points are for arthritis, there must also be a minimum of 3 tender and 3 swollen joints.
    • If participant has rash and Principal Investigator (PI) considers it to be attributable to SLE, participant must consent to skin photograph collection for adjudication.
    • Score must be re-confirmed at the Baseline visit.
  • Physician's Global Assessment (PhGA) ≥ 1 during screening period.
  • Must be on background treatment, stable for 30 days prior to Baseline and throughout the study with antimalarial(s), prednisone (or prednisone equivalent) (≤ 20 mg), azathioprine (≤ 150 mg), mycophenolate (\<2 g), leflunomide (≤ 20 mg), cyclosporine, tacrolimus, and/or methotrexate (MTX) (≤ 20 mg).

    • No combinations of the above with immunomodulators other than prednisone (or equivalents) and antimalarials.

Exclusion criteria

Exclusion Criteria:

  • Participant using intravenous (IV) or intramuscular (IM) greater than or equal to a 40 mg prednisone-equivalent bolus within 30 days of planned randomization.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
341 participants (actual)

Study arms

  • Placebo comparator
    Elsubrutinib placebo/upadacitinib placebo

    Placebo capsule for elsubrutinib once a day by mouth for up to 48 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for up to 48 weeks

    Drug: Placebo for elsubrutinib · Drug: Placebo for upadacitinib

  • Experimental
    ABBV-599 High Dose (Elsubrutinib 60 mg/upadacitinib 30 mg)

    60 mg elsubrutinib capsule once a day by mouth for up to 48 weeks; 30 mg upadacitinib film-coated tablet once a day by mouth for up to 48 weeks

    Drug: Elsubrutinib · Drug: Upadacitinib

  • Experimental
    Elsubrutinib placebo/upadacitinib 30 mg

    Placebo capsule for elsubrutinib once a day by mouth for up to 48 weeks; 30 mg upadacitinib film-coated tablet once a day by mouth for up to 48 weeks

    Drug: Placebo for elsubrutinib · Drug: Upadacitinib

  • Experimental
    ABBV-599 Low Dose (Elsubrutinib 60 mg/upadacitinib 15 mg)

    60 mg elsubrutinib capsule once a day by mouth for up to 24 weeks; 15 mg upadacitinib film-coated tablet once a day by mouth for up to 24 weeks

    Drug: Elsubrutinib · Drug: Upadacitinib

  • Experimental
    Elsubrutinib 60 mg/upadacitinib placebo

    60 mg elsubrutinib capsule once a day by mouth for up to 24 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for up to 24 weeks

    Drug: Elsubrutinib · Drug: Placebo for upadacitinib

Interventions

  • Capsule; Oral

    Also known as: ABBV-105

  • DrugPlacebo for elsubrutinib

    Capsule; Oral

  • Film-coated tablet; Oral

    Also known as: RINVOQ

  • DrugPlacebo for upadacitinib

    Film-coated tablet; Oral

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving SLE Responder Index (SRI)-4 and Steroid Dose ≤ 10 mg Prednisone Equivalent Once a Day (QD) at Week 24

    SLE Responder Index (SRI)-4 is defined as follows with all criteria compared to Baseline: * ≥ 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score * No worsening of the overall condition (\< 0.3 point increase in Physician's Global Assessment \[PhGA\]) * No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores (i.e., no organ system changes from baseline B/C/D/E to A and no more than 1 organ system changes from baseline C/D/E to B). A letter score is assigned to each organ system with following indications: A = severe, B = moderate, C = mild, D = inactive with prior history, and E = inactive with no history.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Percentage of Participants Achieving SLE Responder Index (SRI)-4 at Week 24

    SLE Responder Index (SRI)-4 is defined as follows with all criteria compared to Baseline: * ≥ 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score * No worsening of the overall condition (\< 0.3 point increase in Physician's Global Assessment \[PhGA\]) * No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores (i.e., no organ system changes from baseline B/C/D/E to A and no more than 1 organ system changes from baseline C/D/E to B). A letter score is assigned to each organ system with following indications: A = severe, B = moderate, C = mild, D = inactive with prior history, and E = inactive with no history.

    Time frame: Baseline, Week 24

  2. Percentage of Participants Achieving British Isles Lupus Assessment Group (BILAG) Based Combined Lupus Assessment (BICLA) Response at Week 24

    BICLA is a composite responder index. Achievement of BICLA response is defined as improvement in all initial A and B BILAG scores, with no more than one new BILAG B score without worsening of the overall condition (no worsening in Physician's Global Assessment \[PhGA\], \< 0.3 point increase) and no worsening of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score.

    Time frame: Baseline, Week 24

  3. Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 24

    LLDAS is a state of low disease activity based on Systemic Lupus Erythematosus Disease Activity Index 2000 score (SLEDAI-2K score ≤4 excluding SLEDAI-2K activity in major organ systems), absence of SLE disease activity in major organ systems and new disease activity, Physician's Global Assessment (PhGA ≤1), and concomitant medication usage (steroid dose ≤7.5 mg QD and toleration of immunosuppressive drugs at standard maintenance doses).

    Time frame: Baseline, Week 24

  4. Change From Baseline in Daily Prednisone Dose at Week 24

    Participants' current use of steroid therapy was assessed at each study visit, and the amount of daily prednisone was documented.

    Time frame: From Baseline to Week 24

  5. Number of Flares Per Patient-year by Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) SLEDAI Flare Index Through Week 24

    The SELENA SLEDAI flare index defines mild/moderate or severe SLE flares using the SLEDAI score, definitions of worsening signs and symptoms, treatment changes, and Physician's Global Assessment of Disease Activity.

    Time frame: From Baseline to Week 24

07

Results

Posted Jul 21, 2023

Participant flow

Participant flow — Overall Study
MilestoneElsubrutinib Placebo/Upadacitinib PlaceboABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)Elsubrutinib Placebo/Upadacitinib 30 mgABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg)Elsubrutinib 60 mg/Upadacitinib Placebo
Started7568626967
Completed5252512429
Not completed2316114538
Withdrew: Adverse event25356
Withdrew: Withdrawal by subject104565
Withdrew: Lost to follow-up22201
Withdrew: Covid-19 infection01000
Withdrew: Other, not specified94112
Withdrew: Sponsor decision based on interim analysis data review0003324

Outcome measures

PrimaryPercentage of Participants Achieving SLE Responder Index (SRI)-4 and Steroid Dose ≤ 10 mg Prednisone Equivalent Once a Day (QD) at Week 24

SLE Responder Index (SRI)-4 is defined as follows with all criteria compared to Baseline: * ≥ 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score * No worsening of the overall condition (\< 0.3 point increase in Physician's Global Assessment \[PhGA\]) * No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores (i.e., no organ system changes from baseline B/C/D/E to A and no more than 1 organ system changes from baseline C/D/E to B). A letter score is assigned to each organ system with following indications: A = severe, B = moderate, C = mild, D = inactive with prior history, and E = inactive with no history.

Time frame:
Baseline, Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SLE Responder Index (SRI)-4 and Steroid Dose ≤ 10 mg Prednisone Equivalent Once a Day (QD) at Week 24
percentage of participantsElsubrutinib Placebo/Upadacitinib PlaceboABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)Elsubrutinib Placebo/Upadacitinib 30 mg
Percentage of Participants Achieving SLE Responder Index (SRI)-4 and Steroid Dose ≤ 10 mg Prednisone Equivalent Once a Day (QD) at Week 2437.3 (26.4 to 48.3)48.5 (36.7 to 60.4)54.8 (42.5 to 67.2)
Statistical analysis
  • Elsubrutinib Placebo/Upadacitinib Placebo vs ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) · Cochran-Mantel-Haenszel · p = =0.081 · Response rate difference: 12.8 · 95% CI -1.6 to 27.1
  • Elsubrutinib Placebo/Upadacitinib Placebo vs Elsubrutinib Placebo/Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = =0.028 · Response rate difference: 16.9 · 95% CI 1.8 to 31.9
  • ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) vs Elsubrutinib Placebo/Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = =0.566 · Response rate difference: -4.7 · 95% CI -20.8 to 11.4
SecondaryPercentage of Participants Achieving SLE Responder Index (SRI)-4 at Week 24

SLE Responder Index (SRI)-4 is defined as follows with all criteria compared to Baseline: * ≥ 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score * No worsening of the overall condition (\< 0.3 point increase in Physician's Global Assessment \[PhGA\]) * No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores (i.e., no organ system changes from baseline B/C/D/E to A and no more than 1 organ system changes from baseline C/D/E to B). A letter score is assigned to each organ system with following indications: A = severe, B = moderate, C = mild, D = inactive with prior history, and E = inactive with no history.

Time frame:
Baseline, Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving SLE Responder Index (SRI)-4 at Week 24
percentage of participantsElsubrutinib Placebo/Upadacitinib PlaceboABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)Elsubrutinib Placebo/Upadacitinib 30 mg
Percentage of Participants Achieving SLE Responder Index (SRI)-4 at Week 2438.7 (27.6 to 49.7)54.4 (42.6 to 66.2)56.5 (44.1 to 68.8)
Statistical analysis
  • Elsubrutinib Placebo/Upadacitinib Placebo vs ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) · Cochran-Mantel-Haenszel · p = =0.013 · Response rate difference: 18.3 · 95% CI 3.9 to 32.6
  • Elsubrutinib Placebo/Upadacitinib Placebo vs Elsubrutinib Placebo/Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = =0.018 · Response rate difference: 18.1 · 95% CI 3.0 to 33.2
  • ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) vs Elsubrutinib Placebo/Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = =0.882 · Response rate difference: -1.2 · 95% CI -17.6 to 15.2
SecondaryPercentage of Participants Achieving British Isles Lupus Assessment Group (BILAG) Based Combined Lupus Assessment (BICLA) Response at Week 24

BICLA is a composite responder index. Achievement of BICLA response is defined as improvement in all initial A and B BILAG scores, with no more than one new BILAG B score without worsening of the overall condition (no worsening in Physician's Global Assessment \[PhGA\], \< 0.3 point increase) and no worsening of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score.

Time frame:
Baseline, Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving British Isles Lupus Assessment Group (BILAG) Based Combined Lupus Assessment (BICLA) Response at Week 24
percentage of participantsElsubrutinib Placebo/Upadacitinib PlaceboABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)Elsubrutinib Placebo/Upadacitinib 30 mg
Percentage of Participants Achieving British Isles Lupus Assessment Group (BILAG) Based Combined Lupus Assessment (BICLA) Response at Week 2442.7 (31.5 to 53.9)54.4 (42.6 to 66.2)58.1 (45.8 to 70.3)
Statistical analysis
  • Elsubrutinib Placebo/Upadacitinib Placebo vs ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) · Cochran-Mantel-Haenszel · p = =0.049 · Response rate difference: 14.7 · 95% CI 0.0 to 29.4
  • Elsubrutinib Placebo/Upadacitinib Placebo vs Elsubrutinib Placebo/Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = =0.091 · Response rate difference: 13.9 · 95% CI -2.2 to 30.1
  • ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) vs Elsubrutinib Placebo/Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = =0.447 · Response rate difference: -6.3 · 95% CI -22.5 to 9.9
SecondaryPercentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 24

LLDAS is a state of low disease activity based on Systemic Lupus Erythematosus Disease Activity Index 2000 score (SLEDAI-2K score ≤4 excluding SLEDAI-2K activity in major organ systems), absence of SLE disease activity in major organ systems and new disease activity, Physician's Global Assessment (PhGA ≤1), and concomitant medication usage (steroid dose ≤7.5 mg QD and toleration of immunosuppressive drugs at standard maintenance doses).

Time frame:
Baseline, Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 24
percentage of participantsElsubrutinib Placebo/Upadacitinib PlaceboABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)Elsubrutinib Placebo/Upadacitinib 30 mg
Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 2413.3 (5.6 to 21.0)30.9 (19.9 to 41.9)45.2 (32.8 to 57.5)
Statistical analysis
  • Elsubrutinib Placebo/Upadacitinib Placebo vs ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) · Cochran-Mantel-Haenszel · p = =0.007 · Response rate difference: 16.7 · 95% CI 4.5 to 28.9
  • Elsubrutinib Placebo/Upadacitinib Placebo vs Elsubrutinib Placebo/Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = <0.001 · Response rate difference: 31.0 · 95% CI 18.1 to 44.0
  • ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) vs Elsubrutinib Placebo/Upadacitinib 30 mg · Cochran-Mantel-Haenszel · p = =0.068 · Response rate difference: -13.7 · 95% CI -28.4 to 1.0
SecondaryChange From Baseline in Daily Prednisone Dose at Week 24

Participants' current use of steroid therapy was assessed at each study visit, and the amount of daily prednisone was documented.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · mg
Change From Baseline in Daily Prednisone Dose at Week 24
mgElsubrutinib Placebo/Upadacitinib PlaceboABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)Elsubrutinib Placebo/Upadacitinib 30 mg
Change From Baseline in Daily Prednisone Dose at Week 24-0.65 (-1.57 to 0.28)-0.45 (-1.38 to 0.48)-0.62 (-1.60 to 0.36)
Statistical analysis
  • Elsubrutinib Placebo/Upadacitinib Placebo vs ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) · Mixed-effect model repeat measurement · p = =0.710 · Ls mean difference: 0.20 · 95% CI -0.84 to 1.23
  • Elsubrutinib Placebo/Upadacitinib Placebo vs Elsubrutinib Placebo/Upadacitinib 30 mg · Mixed-effect model repeat measurement · p = =0.963 · Ls mean difference: 0.03 · 95% CI -1.05 to 1.10
  • ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) vs Elsubrutinib Placebo/Upadacitinib 30 mg · Mixed-effect model repeat measurement · p = =0.754 · Ls mean difference: 0.17 · 95% CI -0.90 to 1.25
SecondaryNumber of Flares Per Patient-year by Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) SLEDAI Flare Index Through Week 24

The SELENA SLEDAI flare index defines mild/moderate or severe SLE flares using the SLEDAI score, definitions of worsening signs and symptoms, treatment changes, and Physician's Global Assessment of Disease Activity.

Time frame:
From Baseline to Week 24
Reported as:
Number · Events per patient-year
Number of Flares Per Patient-year by Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) SLEDAI Flare Index Through Week 24
Events per patient-yearElsubrutinib Placebo/Upadacitinib PlaceboABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)Elsubrutinib Placebo/Upadacitinib 30 mg
Mild/Moderate2.45 (1.92 to 2.99)1.39 (0.97 to 1.81)1.76 (1.28 to 2.25)
Severe0.36 (0.16 to 0.56)0.26 (0.08 to 0.44)0.10 (-0.01 to 0.22)
Overall2.81 (2.24 to 3.38)1.65 (1.20 to 2.10)1.87 (1.37 to 2.36)
Statistical analysis
  • Elsubrutinib Placebo/Upadacitinib Placebo vs ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) · Binomial regression · p = =0.002 · Rate difference: -1.06 · 95% CI -1.74 to -0.39
  • Elsubrutinib Placebo/Upadacitinib Placebo vs Elsubrutinib Placebo/Upadacitinib 30 mg · Binomial regression · p = =0.059 · Rate difference: -0.69 · 95% CI -1.41 to 0.03
  • ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) vs Elsubrutinib Placebo/Upadacitinib 30 mg · Binomial regression · p = =0.252 · Rate difference: -0.37 · 95% CI -1.01 to 0.27
  • Elsubrutinib Placebo/Upadacitinib Placebo vs ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) · Binomial regression · p = =0.467 · Rate difference: -0.10 · 95% CI -0.37 to 0.17
  • Elsubrutinib Placebo/Upadacitinib Placebo vs Elsubrutinib Placebo/Upadacitinib 30 mg · Binomial regression · p = =0.033 · Rate difference: -0.26 · 95% CI -0.49 to -0.02
  • ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) vs Elsubrutinib Placebo/Upadacitinib 30 mg · Binomial regression · p = =0.156 · Rate difference: 0.15 · 95% CI -0.06 to 0.37
  • Elsubrutinib Placebo/Upadacitinib Placebo vs ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) · Binomial regression · p = =0.002 · Rate difference: -1.16 · 95% CI -1.89 to -0.44
  • Elsubrutinib Placebo/Upadacitinib Placebo vs Elsubrutinib Placebo/Upadacitinib 30 mg · Binomial regression · p = =0.014 · Rate difference: -0.95 · 95% CI -1.70 to -0.19
  • ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) vs Elsubrutinib Placebo/Upadacitinib 30 mg · Binomial regression · p = =0.526 · Rate difference: -0.22 · 95% CI -0.89 to 0.46

Adverse events

Collected over All-cause mortality is reported from enrollment to end of study; median time on follow-up was 337.0 days, 337.0 days, 338.5 days, 281.0 days, and 295.0 days for the placebo, ABBV-599 High Dose, upadacitinib, ABBV-599 Low Dose, and elsubrutinib groups, respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Elsubrutinib Placebo/Upadacitinib Placebo0/75 (0%)13/75 (17.3%)39/75 (52%)
ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)2/68 (2.9%)7/68 (10.3%)38/68 (55.9%)
Elsubrutinib Placebo/Upadacitinib 30 mg0/62 (0%)13/62 (21%)35/62 (56.5%)
ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg)0/69 (0%)9/69 (13%)28/69 (40.6%)
Elsubrutinib 60 mg/Upadacitinib Placebo2/67 (3%)7/67 (10.4%)36/67 (53.7%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventElsubrutinib Placebo/Upadacitinib PlaceboABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)Elsubrutinib Placebo/Upadacitinib 30 mgABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg)Elsubrutinib 60 mg/Upadacitinib Placebo
PNEUMONIAInfections and infestations0/750/682/621/690/67
SYSTEMIC LUPUS ERYTHEMATOSUSMusculoskeletal and connective tissue disorders1/751/681/622/691/67
URETEROLITHIASISRenal and urinary disorders2/750/680/620/690/67
ABORTION INDUCEDSurgical and medical procedures2/750/680/620/690/67
STRESS CARDIOMYOPATHYCardiac disorders0/750/681/620/690/67
COVID-19 PNEUMONIAInfections and infestations0/751/681/620/690/67
DISSEMINATED VARICELLA ZOSTER VIRUS INFECTIONInfections and infestations0/750/681/620/690/67
GASTROENTERITISInfections and infestations0/750/681/620/690/67
GASTROENTERITIS VIRALInfections and infestations0/750/681/620/690/67
PNEUMOCYSTIS JIROVECII PNEUMONIAInfections and infestations0/750/681/620/690/67
Most frequent other events
Showing 10 of 20
Most frequent other events
EventElsubrutinib Placebo/Upadacitinib PlaceboABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)Elsubrutinib Placebo/Upadacitinib 30 mgABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg)Elsubrutinib 60 mg/Upadacitinib Placebo
URINARY TRACT INFECTIONInfections and infestations9/758/6811/625/694/67
HEADACHENervous system disorders9/754/682/627/6910/67
COVID-19Infections and infestations8/753/687/622/698/67
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations8/757/685/625/695/67
HERPES ZOSTERInfections and infestations3/757/683/623/691/67
NAUSEAGastrointestinal disorders6/754/684/622/696/67
NASOPHARYNGITISInfections and infestations3/756/681/625/690/67
DIARRHOEAGastrointestinal disorders6/753/684/623/692/67
PYREXIAGeneral disorders6/753/683/622/691/67
ARTHRALGIAMusculoskeletal and connective tissue disorders5/753/681/622/695/67

Baseline characteristics

Full Analysis Set: all randomized participants who received at least 1 dose of study drug

Age, Continuous
Age, Continuous(years)Elsubrutinib Placebo/Upadacitinib PlaceboABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)Elsubrutinib Placebo/Upadacitinib 30 mgABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg)Elsubrutinib 60 mg/Upadacitinib PlaceboTotal
Mean41.7 ± 12.0542.7 ± 11.2742.5 ± 11.8941.4 ± 11.8542.0 ± 11.8442.1 ± 11.73
Sex: Female, Male
Sex: Female, Male(Participants)Elsubrutinib Placebo/Upadacitinib PlaceboABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)Elsubrutinib Placebo/Upadacitinib 30 mgABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg)Elsubrutinib 60 mg/Upadacitinib PlaceboTotal
Female7562576362319
Male0656522
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Elsubrutinib Placebo/Upadacitinib PlaceboABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)Elsubrutinib Placebo/Upadacitinib 30 mgABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg)Elsubrutinib 60 mg/Upadacitinib PlaceboTotal
American Indian or Alaska Native3301411
Asian23141313972
Native Hawaiian or Other Pacific Islander000000
Black or African American4498631
White4345344544211
More than one race2262416
Unknown or Not Reported000000
Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score
Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score(units on a scale)Elsubrutinib Placebo/Upadacitinib PlaceboABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)Elsubrutinib Placebo/Upadacitinib 30 mgABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg)Elsubrutinib 60 mg/Upadacitinib PlaceboTotal
Mean9.1 ± 3.888.9 ± 2.759.0 ± 2.758.8 ± 2.869.2 ± 3.189.0 ± 3.12
Physician's Global Assessment (PhGA) score
Physician's Global Assessment (PhGA) score(units on a scale)Elsubrutinib Placebo/Upadacitinib PlaceboABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)Elsubrutinib Placebo/Upadacitinib 30 mgABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg)Elsubrutinib 60 mg/Upadacitinib PlaceboTotal
Mean1.75 ± 0.4401.80 ± 0.4171.70 ± 0.4381.77 ± 0.4221.77 ± 0.3921.76 ± 0.421
Daily dose of corticosteroid
Daily dose of corticosteroid(mg/day)Elsubrutinib Placebo/Upadacitinib PlaceboABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg)Elsubrutinib Placebo/Upadacitinib 30 mgABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg)Elsubrutinib 60 mg/Upadacitinib PlaceboTotal
Mean7.937 ± 7.12706.743 ± 6.37366.242 ± 6.09206.891 ± 6.10566.291 ± 6.10966.856 ± 6.3885
08

Study locations

160 sites
  • Arizona Arthritis & Rheumatology Research, PLLC /ID# 214522
    Mesa, Arizona 85210-6871, United States
  • AZ Arthritis and Rheumotology Research, PLLC /ID# 211329
    Phoenix, Arizona 85032-9306, United States
  • AZ Arthritis and Rheumotology Research, PLLC /ID# 214267
    Phoenix, Arizona 85032-9306, United States
  • Arthritis and Rheumatism Associates /ID# 211411
    Jonesboro, Arkansas 72401-6251, United States
  • Wallace Rheumatic Studies Center, LLC /ID# 211600
    Beverly Hills, California 90211, United States
  • Arthritis & Osteo Medical Ctr /ID# 228235
    La Palma, California 90623-1728, United States
  • Valerius Medical Group & Research Center /ID# 211599
    Los Alamitos, California 90720-5402, United States
  • East Bay Rheumatology Medical /ID# 211638
    San Leandro, California 94578, United States
  • The Lundquist Institute at Harbor-UCLA Medical Center /ID# 213402
    Torrance, California 90502, United States
  • Medvin Clinical Research /ID# 211996
    Tujunga, California 91042-2706, United States
  • Inland Rheum Clin Trials Inc. /ID# 213617
    Upland, California 91786, United States
  • University of Colorado Hospital /ID# 211314
    Aurora, Colorado 80045, United States
  • Yale University /ID# 212824
    New Haven, Connecticut 06510, United States
  • Medstar Health Research Institute /ID# 213335
    Washington, District of Columbia 20010, United States
  • Arthritis & Rheumatic Disease Specialties /ID# 214052
    Aventura, Florida 33180, United States
  • LeJenue Research Associates /ID# 212327
    Miami, Florida 33126, United States
  • Ctr Arthritis & Rheumatic Dise /ID# 212326
    Miami, Florida 33173, United States
  • Millennium Research /ID# 219099
    Ormond Beach, Florida 32174, United States
  • IRIS Research and Development, LLC /ID# 213053
    Plantation, Florida 33324, United States
  • West Broward Rheumatology Associates /ID# 211881
    Tamarac, Florida 33321, United States
  • BayCare Medical Group, Inc. /ID# 218818
    Tampa, Florida 33614-7101, United States
  • Affinity Clinical Research /ID# 211496
    Oak Brook, Illinois 60523-1245, United States
  • Deerbrook Medical Associates /ID# 212251
    Vernon Hills, Illinois 60061, United States
  • Qualmedica Research, LLC /ID# 214765
    Evansville, Indiana 47714-0805, United States
  • University of Iowa Hospitals and Clinics /ID# 215246
    Iowa City, Iowa 52242, United States
  • The Center for Rheumatology and Bone Research /ID# 211610
    Wheaton, Maryland 20902, United States
  • Beth Israel Deaconess Medical Center /ID# 212321
    Boston, Massachusetts 02215-5400, United States
  • Henry Ford Health System /ID# 211676
    Detroit, Michigan 48202, United States
  • June DO, PC /ID# 211674
    Lansing, Michigan 48910, United States
  • West County Rheumatology /ID# 225051
    Saint Louis, Missouri 63131-1703, United States
  • NYU Langone Ambulatory Care Brooklyn Heights /ID# 211548
    Brooklyn, New York 11201, United States
  • NYU Langone Orthopedic Center /ID# 213620
    New York, New York 10016-2772, United States
  • Ohio State University - Wexner Medical Center /ID# 211636
    Columbus, Ohio 43210-1229, United States
  • STAT Research, Inc. /ID# 211404
    Vandalia, Ohio 45377-9464, United States
  • Premier Rheumatology of Oklahoma /ID# 213850
    Tulsa, Oklahoma 74136-2117, United States
  • Allegheny Health Network Research Institute /ID# 211607
    Pittsburgh, Pennsylvania 15224, United States
  • Univ TN Health Sciences Ctr /ID# 212177
    Memphis, Tennessee 38103, United States
  • Dr. Ramesh Gupta /ID# 213381
    Memphis, Tennessee 38119, United States
  • Tekton Research, Inc. /ID# 211521
    Austin, Texas 78745, United States
  • Tekton Research, Inc. /ID# 214182
    Austin, Texas 78745, United States
  • Trinity Universal Research Associates - Carrollton /ID# 211527
    Carrollton, Texas 75007, United States
  • Accurate Clinical Management /ID# 213571
    Houston, Texas 77084, United States
  • West Texas Clinical Research /ID# 211529
    Lubbock, Texas 79424, United States
  • SW Rheumatology Res. LLC /ID# 211520
    Mesquite, Texas 75150, United States
  • Carilion Clinic /ID# 213500
    Roanoke, Virginia 24016, United States
  • Virginia Mason Medical Center /ID# 211457
    Seattle, Washington 98101, United States
  • Rheumatology and Pulmonary Clinic /ID# 211398
    Beckley, West Virginia 25801, United States
  • Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich /ID# 221685
    Ciudad Autonoma Buenos Aires, Buenos Aires 1426, Argentina
  • Hospital Interzonal General de Agudos General Jose de San Martin /ID# 211679
    La Plata, Buenos Aires 1900, Argentina
  • CER Instituto Medico /ID# 222757
    Quilmes, Buenos Aires 1878, Argentina
  • Aprillus Asistencia e Investigacion /ID# 211630
    Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires 1046, Argentina
  • Centro de Enfermedades del Hígado y Aparato Digestivo /ID# 211634
    Rosario, Santa Fe 2000, Argentina
  • Instituto CAICI S.R.L /ID# 211633
    Rosario, Santa Fe 2000, Argentina
  • Centro de Investigaciones Medicas Tucuman /ID# 212714
    San Miguel de Tucuman, Tucuman 4000, Argentina
  • Investigaciones Clinicas Tucuman /ID# 211942
    San Miguel de Tucuman, Tucuman 4000, Argentina
  • Hospital Cordoba /ID# 212200
    Cordoba, 5000, Argentina
  • Emeritus Research Sydney /ID# 222983
    Botany, New South Wales 2019, Australia
  • Royal North Shore Hospital /ID# 222982
    St Leonards, New South Wales 2065, Australia
  • Royal Brisbane and Women's Hospital /ID# 212667
    Herston, Queensland 4029, Australia
  • Rheumatology Research Unit Sunshine Coast /ID# 211902
    Maroochydore, Queensland 4558, Australia
  • Griffith University /ID# 223543
    Southport, Queensland 4222, Australia
  • The Queen Elizabeth Hospital /ID# 211901
    Woodville South, South Australia 5011, Australia
  • Emeritus Research /ID# 211903
    Camberwell, Victoria 3124, Australia
  • Monash Medical Centre /ID# 212313
    Clayton, Victoria 3168, Australia
  • St Vincent's Hospital Melbourne /ID# 212311
    Fitzroy Melbourne, Victoria 3065, Australia
  • UMHAT Kaspela EOOD /ID# 223141
    Plovdiv, 4001, Bulgaria
  • UMHAT Sveti Ivan Rilski /ID# 223139
    Sofia, 1431, Bulgaria
  • UMHAT Sveti Ivan Rilski /ID# 223140
    Sofia, 1431, Bulgaria
  • Hamilton Health Sciences - McMaster University Medical Centre /ID# 212662
    Hamilton, Ontario L8S 4K1, Canada
  • St. Josephs Health Care Centre /ID# 212331
    London, Ontario N6A 4V2, Canada
  • Toronto Western Hospital /ID# 213336
    Toronto, Ontario M5T 2S8, Canada
  • Diex Recherche Sherbrooke Inc. /ID# 217734
    Sherbrooke, Quebec J1L 0H8, Canada
  • Anhui Provincial Hospital /ID# 211812
    Hefei, Anhui 230001, China
  • Peking Union Medical College Hospital /ID# 211614
    Beijing, Beijing 100730, China
  • Guangdong Provincial People's Hospital /ID# 211811
    Guangzhou, Guangdong 510080, China
  • Xiangya Hospital Central South University /ID# 212919
    Changsha, Hunan 410008, China
  • Jiangsu Province Hospital /ID# 211818
    Nanjing, Jiangsu 210029, China
  • Huashan Hospital, Fudan University /ID# 213976
    Shanghai, Shanghai 200040, China
  • Shanghai Changhai Hospital /ID# 211819
    Shanghai, Shanghai 200433, China
  • People's Hospital of Xinjiang /ID# 211821
    Urumqi, 830001, China
  • Centro Integral de Reumatologia del Caribe Circaribe SAS /ID# 211894
    Barranquilla, Atlantico 80002, Colombia
  • Centro de Investigacion en Reumatologia y Especialidades Medicas- CIREEM SAS /ID# 211895
    Bogota, Cundinamarca 110221, Colombia
  • Preventive Care Sas /Id# 211896
    Chia, Cundinamarca 250001, Colombia
  • Healthy Medical Center SAS /ID# 211899
    Zipaquira, Cundinamarca 250252, Colombia
  • Clinica Universitaria Bolivari /ID# 211897
    Medellin, 050034, Colombia
  • CHRU Lille - Hopital Claude Huriez /ID# 211829
    Lille, Hauts-de-France 59037, France
  • CHU Bordeaux - Hopital Pellegrin /ID# 211832
    Bordeaux, 33000, France
  • AP-HP - Hôpital Bicêtre /ID# 211968
    Le Kremlin Bicetre, 94270, France
  • Hopital Pitie Salpetriere /ID# 211831
    Paris, 75013, France
  • CHU Strasbourg - Hopital Civil /ID# 211981
    Strasbourg cedex, 67091, France
  • Universitaetsklinikum Duesseldorf /ID# 212408
    Düsseldorf, Nordrhein-Westfalen 40225, Germany
  • Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 212674
    Kiel, Schleswig-Holstein 24105, Germany
  • Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 211988
    Berlin, 10117, Germany
  • Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 212770
    Dresden, 01307, Germany
  • Debreceni Egyetem Klinikai Kozpont /ID# 212042
    Debrecen, Hajdu-Bihar 4032, Hungary
  • Vital Medical Center Orvosi es Fogaszati Kozpont /ID# 212796
    Veszprém, Veszprem 8200, Hungary
  • Orszagos Reumatologiai es Fizioterapias Intezet /ID# 211827
    Budapest, 1023, Hungary
  • Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz /ID# 216971
    Gyula, 5700, Hungary
  • Azienda Ospedaliero-Universitaria di Ferrara-Arcispedale Sant Anna /ID# 211861
    Cona, Ferrara 44124, Italy
  • Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 212195
    Rome, Lazio 00161, Italy

Showing the first 100 of 160 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2. PubMed 33687069 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Jan 2022, 29 months.

Results were first posted in Jul 2023, 1 year 6 months after primary completion. A results delay was requested in Dec 2022.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 29 months is close to that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2019
First posted
Jun 7, 2019
StartActual
Jul 25, 2019
Primary completionActual
Jan 19, 2022
CompletionActual
Jul 14, 2022
Results delay requested
Dec 19, 2022
Results first posted
Jul 21, 2023
Last update
Jul 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03978520
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 7, 2019
Start date
Jul 25, 2019
Primary completion
Jan 19, 2022
Completion
Jul 14, 2022
Results posted
Jul 21, 2023
Last update
Jul 21, 2023

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elsubrutinib · Upadacitinib

Start the discussion